10/3/2018. Antonio Gómez PhD. Sevilla, September 26 th 2018

Transcription

1 Antonio Gómez PhD DRUG DISCOVERY PHARMA BIOTECH FORUM DRUG DISCOVERY PHARMA-BIOTECH FORUM Sevilla, September 26 th

2 Johnson & Johnson is the largest and most diversified ifi dhealthcare h company in the world More than 130 years creating value through innovation Three business segments: pharmaceuticals, medical devices, consumer >250 Operating Companies Selling products in more than 175 countries Over 130,000 employees worldwide 2

3 J&J Innovation composition Innovation Centers Janssen Business Development JLABS JJDC Early stage deals Mid- and late-stage deals from any source Incubates health care start- ups 40+ years of VC investing Academic centers and small/medium cap biotech. Licensing, Research Collaborations, Sponsored Research etc. Early-, mid- and latestage deals with established biotech and pharma companies Collaboration, Licensing and M&A Expertise 10 sites globally: BE just announced NYC opening June 2018 Shanghai opening 2019 $1.5B total capital deployed in last 4 years: Partnership with Innovation Centers to form new companies on the rise San Francisco, Boston, London, Shanghai Single Point of Entry jnjinnovation.com 3

4 Global Johnson & Johnson Innovation Network 2018 California Innovation Center San Francisco, CA Alberta JLABS Toronto Canada JLABS Lowell EMEA Innovation Center London, U.K. Asia Pacific Innovation Center Shanghai, China M2D2) Boston Innovation Center Cambridge, MA JLABS Boston JLABS Beerse, Belgium Japan Seoul BE) JLINX transition JJI PO at Bio Hub, Hub JLABS N New Y York k Seoul, Korea NYC) JLABS Bay Area Opening 2018 QB3) Singapore FutuRx Israel, Weizmann Science Park JLABS South San Francisco ( t d l (standalone) ) SSF) JLABS San Diego JLABS Houston Texas Medical Center Shanghai) Opening 2019 Sydney La Jolla (flagship/standalone) JJIPO@QUT TMC CDI C Innovation Center (IC) JLABS Shanghai, China JJIPO@Monash IC Offices JLABS Partnering Office Med Devices 4

5 We form value generating collaborations Flexible deal structures Funding Company incubation R&D expertise Business development 5

6 Enables Collaborations/Partnership IDEA CONCEPT JLABS PRECLINICAL POC CLINICAL POC PATIENT Incubation (JLABS) JJIC Advice and mentorship EIR/ Innovator Programs $ $ NewCo Creation Sponsored research R&D collaborations JBD JJDC Licensing and M&A Venture funding 6

7 7

8 Biomedical R&D in Spain 8

9 Our main initiative in Spain: I2D2 Call for projects with disruptive innovation en las areas of interest of J&J New model in public-private partnership Co-funded between Janssen Spain, Xunta de Galicia and Kaertor 9

10 I2D2 Call Scheme Sept 17 Nov 17 Dec 18 Jun 19 Call launch Submissions Selection Project-related work Evaluation 10

11 I2D2 Status More than 150 Expressions of Interest received Three projects selected to proceed to the incubation stage Selective HDAC6 inhibitors for neurodegenerative conditions Inhibition of p38 as a treatment for steatosis Allosteric modulators of the dopamine D1 receptor for PD 11

12 Thank you The patients are waiting 12